USE OF ADAMTS13 FOR THE TREATMENT, RELIEF AND / OR PREVENTION OF VASO-OCCLUSIVE CRISIS IN SICKLE CELL ANEMY, ACUTE LUNG LESION AND / OR ACUTE RESPIRATORY STRESS SYNDROME
DE602017092963T2Active Publication Date: 2025-12-03TAKEDA PHARMA CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- DE602017092963
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-08-04
- Filing Date
- 2017-08-04
- Publication Date
- 2025-12-03
- Estimated Expiration
- 2037-08-04
AI Technical Summary
Technical Problem
Current treatments for sickle cell disease (SCD) are inadequate in managing vaso-occlusive crises (VOC) and associated complications, and there is a need for improved therapies to reduce symptoms, prevent complications, and improve life quality and expectancy.
Method used
Administering a therapeutically effective amount of ADAMTS13, a protein that cleaves von Willebrand factor, to treat, ameliorate, or prevent VOC in SCD patients, thereby reducing inflammation, vasoconstriction, platelet aggregation, and organ damage.
Benefits of technology
ADAMTS13 administration reduces the frequency and severity of VOC episodes, improves survival and lung function, and minimizes organ damage, while maintaining effective ADAMTS13 activity levels in the body.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.